Cabergoline in Parkinson's disease complicated by motor fluctuations

Movement Disorders

Volumn 11, Issue 5, 1996, Pages 495-500

  Geminiani, Giuliano ^a   Fetoni, Vincenza ^a   Genitrini, Silvia ^a   Giovannini, Paolo ^a   Tamma, Filippo ^a   Caraceni, Tommaso ^a  

^a DEPARTMENT OF NEUROSURGERY   (Italy)

Author keywords

Cabergoline; Dopamine agonist; Dyskinesias; Motor fluctuations; Parkinson's disease

Indexed keywords

CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT;

ADULT; AGED; ANKLE EDEMA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DYSKINESIA; GASTROINTESTINAL SYMPTOM; HUMAN; LUNG FIBROSIS; MOTOR DYSFUNCTION; ORAL DRUG ADMINISTRATION; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PLEURA EFFUSION; PRIORITY JOURNAL;

EID: 0029792374     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.870110504     Document Type: Article

References (11)

1. Marsden CD, Parkes JD. On-off effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet 1976; 1:292-296.
2. Shoulson I, Glaubiger GA, Chase TN. On-off response. Clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients. Neurology 1975;25:1144-1148.
3. Lera G, Vaamonde J, Rodriguez M, Obeso JA. Cabergoline in Parkinson's disease: long term follow-up. Neurology 1993;43:2587-2590.
4. Frankel JP, Lees AJ, Kempster PA, Stern GM. Subcutaneous apomorphine in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry 1990;53:96-101.
5. Cederbaum JM. The promise and limitations of controlled release oral levodopa administration. Clin Neuropharmacol 1989;12:147-166.
6. Persiani S, Sassolas G, Piscitelli G, et al. Pharmacodynamics and relative bioavailability of cabergoline tablets vs solution in healthy volunteers. J Pharm Sci. 1994;83:1421-1424.
7. Jori MC, Dubini A. Cabergoline. In: Caraceni T, Nappi G, eds. Focus on Parkinson's disease. Milan, Italy: Masson, 1991:221-226.
8. Hutton JT, Morris JL, Brewer MA. Controlled study of the antiparkinsonian activity and tolerability of cabergoline. Neurology 1993;43:613-616.
9. Lieberman A, Imke S, Muenter M, et al. Multicenter study of cabergoline, a long-acting dopamine receptor agonist, in Parkinson's disease patients with fluctuating responses to levodopa/carbidopa. Neurology 1993;43:1981-1984.
10. Rinne UK. Pleuropulmonary changes during long-term bromocriptine treatment for Parkinson disease. Lancet 1981;1: 44.
11. McElvaney NG, Wilcox PG, Churg A, Fleetham JA. Pleuropulmonary disease during bromocriptine treatment of Parkinson's disease. Arch Intern Med 1988;148:2231-2236.